中国医学科学院药物研究所-九游官网下载

近年来主持国家及省部科研项目5项、包括主持国家自然科学基金项目面上项目，联合基金项目、国家重点研发计划项目、北京市自然科学基金项目等，参与科研项目10余项。以（共同）第一作者或（共同）通讯作者发表的sci文章17篇，参编学术论著5部，申请专利7项，兼任北京药理学会神经精神药理专业委员会副秘书长、中国药理学会补益药药理专业委员会副秘书长、国家自然科学基金通信评审专家、北京市自然科学基金评审专家库成员和acta pharmacologica sinica, european journal of pharmacology, journal of ethnopharmacology, international immunopharmacology等sci期刊审稿人。

主要从事神经药理学研究，特别是针对我国科学家自主发现的新型基因cklf1为脑卒中治疗靶点的系统生物学与药理学研究，阐明了cklf1在卒中后的病理学作用，解析了cklf1的诱导表达机制，阐述了cklf1作为脑卒中治疗靶点的可行性与优越性。在此基础上，构建了以cklf1为靶点的抗脑卒中创新药物发现与评价体系，发现了一系列天然产物来源与人工合成的cklf1抑制剂均具有良好的抗脑卒中药理学功效，为缺血性脑卒中的治疗提供了新的思路与理论基础。

1. a breakdown of metabolic reprogramming in microglia induced by cklf1 exacerbates immune tolerance in ischemic stroke. wen-yu ma, qing-lin wu, sha-sha wang, hong-yun wang, jun-rui ye, hong-shuo sun, zhong-ping feng, wen-bin he, shi-feng chu*, zhao zhang*, nai-hong chen* journal of neuroinflammation. 2023;20(1):97.
2. a small molecular antagonist of ccr5 promoted neural repair post stroke. qing-lin wu, li-yuan cui, wen-yu ma, sha-sha wang, zhao zhang, zhong-ping feng, hong-shuo sun, shi-feng chu*, wen-bin he*, nai-hong chen*. acta pharmacol sin. 2023. doi: 10.1038/s41401-023-01100-y.
3. ginsenoside rg1 protects against ischemic/reperfusion-induced neuronal injury through mir-144/nrf2/are pathway. shi-feng chu, zhao zhang, xin zhou, wen-bin he, chen chen, piao luo, dan-dan liu, qi-di ai, hai-fan gong, zhen-zhen wang, hong-shuo sun, zhong-ping feng, nai-hong chen*. acta pharmacol sin. 2019;40(1):13-25.
4. low corticosterone levels attenuate late life depression and enhance glutamatergic neurotransmission in female rats. shi-feng chu, zhao zhang, xin zhou, wen-bin he, bo yang, li-yuan cui, hong-yuan he, zhen-zhen wang, nai-hong chen*. acta pharmacol sin. 2021;42(6):848-860.
5. upregulating the expression of survivin-hbxip complex contributes to the protective role of imm-h004 in transient global cerebral ischemia/reperfusion. shi-feng chu, zhao zhang, wei zhang, mei-jin zhang, yan gao, ning han, wei zuo, hui-yong huang, nai-hong chen*. mol neurobiol. 2017;54(1):524-540.
6. the anti-dementia drug candidate, (-)-clausenamide, improves memory impairment through its multi-target effect. shi-feng chu, shao-lin liu, wen-zhen duan, yong cheng, xue-ying jiang, chuan-jiang zhu, kang tang, run-sheng wang, lin xu, xiao-ying wang, xiao-ming yu, ke-mei wu, yan wang, mu-zou wang, hui-yong huang, jun-tian zhang*. pharmacol ther. 2016;162:179-87.
7. combination of monoammonium glycyrrhizinate and cysteine hydrochloride ameliorated lipopolysaccharide/galactosamine-induced acute liver injury through nrf2/are pathway. shi-feng chu, zi-quan niu, qing-xin guo, hao-zhi bi, xin-yu li, fang-fang li, zhao zhang, wen-bin he, peng cao, nai-hong chen*, xiao-yun sun*. eur j pharmacol. 2020;882:173258.
8. up-regulation of nrf2/p62/keap1 involves in the anti-fibrotic effect of combination of monoammonium glycyrrhizinate and cysteine hydrochloride induced by ccl4. shi-feng chu, hao-zhi bi, xin-yu li, li-yuan cui, wen-bin he, ya-juan tian, fei liu, ge gao, zheng-bin wang, nai-hong chen*, hong wang*. eur j pharmacol. 2021;913:174628.
9. hmgb1参与人参皂苷rg1改善糖尿病缺血性脑卒中的作用. 楚世峰，周欣，张钊，陈晨，罗飘，陈乃宏*. 药学学报, 2018,53(6):958-965.
10. rtp801 is a critical factor in the neurodegeneration process of a53t α-synuclein in a mouse model of parkinson's disease under chronic restraint stress. zhao zhang#, shi-feng chu#, sha-sha wang, yi-na jiang, yan gao, peng-fei yang, qi-di ai, nai-hong chen*. br j pharmacol. 2018;175(4):590-605.
11. a20 as a novel target for the anti-neuroinflammatory effect of chrysin via inhibition of nf-κb signaling pathway. zhi-peng li#, shi-feng chu#, wen-bin he, zhao zhang, jia-qi liu, li-yuan cui, xu yan, de-fang li, nai-hong chen*. brain behav immun. 2019;79:228-235.
12. neuronal chemokine-like-factor 1 (cklf1) up-regulation promotes m1 polarization of microglia in rat brain after stroke. xin zhou, ya-ni zhang, fang-fang li, zhao zhang, li-yuan cui, hong-yuan he, xu yan, wen-bin he, hong-shuo sun, zhong-ping feng, shi-feng chu*, nai-hong chen*. acta pharmacol sin. 2022;43(5):1217-1230.
13. regulatory t cells in ischemic stroke. hong-yun wang, jun-rui ye, li-yuan cui, shi-feng chu*, nai-hong chen* acta pharmacol sin. 2022;43(1):1-9.
14. the progress of chemokines and chemokine receptors in autism spectrum disorders. jun-rui ye, hong-yun wang, li-yuan cui, shi-feng chu*, nai-hong chen*. brain res bull. 2021;174:268-280.
15. korean red ginseng alleviate depressive disorder by improving astrocyte gap junction function. qing-lian zheng, hao-yu zhu, xin xu, shi-feng chu*, li-yuan cui, yi-xiao dong, ying-jiao liu, jia-hong zhan, zhen-zhen wang, nai-hong chen* j ethnopharmacol. 2021;281:114466.
16. the versatile role of trem2 in regulating of microglia fate in the ischemic stroke. wen-yu ma, sha-sha wang, qing-lin wu, xin zhou, shi-feng chu*, nai-hong chen*. int immunopharmacol. 2022;109:108733.
17. cklf1/ccr5 axis is involved in neutrophils migration of rats with transient cerebral ischemia. chen chen, shi-feng chu*, qi-di ai, zhao zhang, nai-hong chen*. int immunopharmacol. 2020;85:106577.

1. 药理学实验操作教程（全视频展示），编委，中国协和医科大学出版社，2021。
2. 认知科学与认知药理学，编者，化学工业出版社，2020。
3. natural small molecule drugs from plants, 编者，spring press, 2019。
4. 天然小分子药物-源自植物的小分子药物，编者，人民卫生出版社，2018。
5. 自由基氧化损伤与抗氧化剂，编者，化学工业出版社，2016。

1. 一种香豆素衍生物代谢产物的制备及其在防治脑缺血和阿尔茨海默病中的应用，陈乃宏，李燕， 戴均贵，宋修云，盛莉，乐田，楚世峰，张梓倩，解可波，谭圳，2021-01-12。
2. ccr5过表达的人源细胞株的建立及应用，陈乃宏，崔丽媛，楚世峰，张钊，闫旭，2020-12-03。
3. 一种以cklf1-ccr5相互作用为靶标的药物筛选方法，陈乃宏，叶君锐， 楚世峰， 张钊，闫旭，2022-1-26。
4. 一种以cklf1-ccr4相互作用为靶标的药物筛选方法，陈乃宏，楚世峰，叶君锐，张钊，闫旭，2022-6-21。
5. 一种化合物在制备预防或治疗缺血性脑中风药物中的应用，陈乃宏，张钊，楚世峰，崔丽媛，闫旭，2021-7-24。
6. 一种ccr5抑制剂及其应用，陈乃宏，张钊，楚世峰，崔丽媛，王洪蕴，叶君锐，王真真，闫旭，2021-10-9。
7. 一种治疗神经退行性疾病的注射用浓溶液及其制备方法，高钟镐，张东明，黄伟，李燕，陈乃宏，辛欣，臧应达，盛莉，楚世峰，李创军，马洁，2020-10-21。